- In March 2020, Agilent Technologies Inc. launched Agilent GenetiSure Cyto microarrays for prenatal and postnatal research
- In April 2020, an international collaborative alliance to improve customised medication in cancer using IndivuType, the business's multi-omics database, was established by the oncology company Indivumed GmbH
Frequently Asked Questions
The market is segmented based on Segmentation, By Tumor Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Others), Technology (Microarray, Real-Time Quantitative, Polymerase Chain Reaction (Q-PCR), Sequencing Technologies), Product (Consumables, Instrument, Others), Application (Diagnostics and Disease Profiling, Drug Discovery, Others) – Industry Trends and Forecast to 2032
.
The Global Tumor Transcriptomics Market size was valued at USD 9.63 USD Billion in 2024.
The Global Tumor Transcriptomics Market is projected to grow at a CAGR of 10.45% during the forecast period of 2025 to 2032.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
